PPCM: Peripartum Cardiomyopathy , The Heart Attack Nobody Calls a Heart Attack

Peripartum cardiomyopathy is a pregnancy-associated heart failure syndrome affecting 1 in 968 US deliveries, with Black women experiencing 5.3-fold higher incidence than White women. The European Society of Cardiology defines PPCM as new systolic dysfunction with ejection fraction below 45% occurring in the last month of pregnancy or within five months of delivery, after excluding other causes. Despite causing 8% maternal mortality at median 8.3-year follow-up, PPCM is initially misdiagnosed as postpartum depression or anxiety in over one-third of cases, delaying treatment by a median of seven days.

She was exhausted, short of breath, and could not sleep lying flat. Her OB said postpartum fatigue is normal. It was not normal. Her ejection fraction was 28%.

I see this patient three or four times a year. She is usually between 28 and 42 years old. She delivered her baby two to eight weeks ago. She has visited her obstetrician at least once since delivery, sometimes twice. At each visit, she mentioned the same symptoms: crushing fatigue, racing heart, inability to catch her breath while climbing stairs or carrying the baby. Each time, she heard the same response. This is normal. You just had a baby. Give yourself time.

By the time she reaches my clinic, she has heart failure. Not the vague, metaphorical heart failure that people invoke when they are overwhelmed. Actual, measurable heart failure. Her left ventricle has dilated. Her ejection fraction has dropped from the normal 55-60% to somewhere between 20% and 35%. Her heart cannot pump blood effectively. Without treatment, her risk of death is significant.

The tragedy is not that peripartum cardiomyopathy exists. The tragedy is that it is predictable, treatable, and routinely missed.

What Peripartum Cardiomyopathy Actually Is

The European Society of Cardiology Working Group on PPCM established the diagnostic criteria in 2010. PPCM is an idiopathic cardiomyopathy presenting with heart failure secondary to left ventricular systolic dysfunction toward the end of pregnancy or in the months following delivery. The ejection fraction must be below 45%. There must be no other identifiable cause for the heart failure. The diagnosis is one of exclusion, but the clinical presentation is often textbook if you know what to look for.

The incidence varies dramatically by population. A 2015 analysis of the Nationwide Inpatient Sample by Kolte and colleagues in Circulation found an overall US incidence of 1 in 968 live births. That number conceals a stark disparity. For White women, the incidence was 1 in 2,175 deliveries. For Black women, the incidence was 1 in 407 deliveries. This represents a 5.3-fold difference. 5 / Solid

A 2024 population study from the United Kingdom published in the European Heart Journal followed PPCM patients for a median of 8.3 years. The findings were sobering. Eight percent of women died during follow-up. Seventy-five percent required at least one rehospitalization. This is not a condition that resolves spontaneously and fades from memory. This is a chronic disease with lifelong implications.

The heart does not simply “get tired” during pregnancy. Pregnancy demands a 50% increase in cardiac output. Blood volume expands by 45%. Heart rate rises. Systemic vascular resistance drops. For most women, the cardiovascular system adapts. For women with PPCM, something goes wrong at the cellular level.

The Prolactin Mechanism

The leading mechanistic theory centers on prolactin, the hormone that drives milk production. In 2007, Hilfiker-Kleiner and colleagues published landmark research in Cell identifying a 16-kDa fragment of prolactin as directly cardiotoxic.

Here is the mechanism. Under conditions of oxidative stress, an enzyme called cathepsin D cleaves prolactin into a smaller fragment called vasoinhibin. This 16-kDa fragment does not stimulate milk production. Instead, it triggers endothelial cell apoptosis. It impairs cardiomyocyte metabolism. It damages the microvasculature of the heart. 4 / Promising

This explains why PPCM clusters around delivery. Prolactin levels surge in the peripartum period. If a woman has underlying oxidative stress, perhaps from preeclampsia, chronic hypertension, or genetic susceptibility, the prolactin surge becomes a trigger for myocardial damage.

The prolactin mechanism also explains why bromocriptine, a drug that blocks prolactin secretion, has shown benefit in some PPCM trials. In a German randomized trial, women treated with bromocriptine in addition to standard heart failure therapy had better recovery of ejection fraction at six months than women treated with standard therapy alone. The therapy is not universally adopted. It requires suppression of breastfeeding, which many women strongly prefer to preserve. But the mechanism illuminates why pregnancy itself can be a cardiac stressor.

I call this framework the Peripartum Vascular Inflection Window. The last month of pregnancy and the first five months postpartum represent a period of maximum hormonal and hemodynamic stress on the cardiovascular system. For susceptible women, this window is when damage accumulates. After this window closes, the trigger disappears, but the damage may persist.

The Symptom That Should Trigger an Echocardiogram

Normal postpartum recovery involves fatigue. Sleep deprivation. Difficulty concentrating. These symptoms occur in nearly every new mother. The challenge for clinicians is distinguishing normal adaptation from pathological heart failure.

The single most specific symptom is orthopnea. Orthopnea means dyspnea when lying flat. The woman cannot sleep horizontally. She needs two, three, four pillows to breathe comfortably. She may describe waking up gasping for air.

In a prospective cohort study by Sliwa and colleagues, 89% of women with PPCM reported orthopnea. Fewer than 5% of healthy postpartum controls reported the same symptom. That is an 18-fold difference in prevalence. 5 / Solid

The other red flag symptoms include paroxysmal nocturnal dyspnea, which is waking suddenly at night unable to breathe. Persistent cough, especially when lying down. Rapid weight gain from fluid retention. Lower extremity edema that is disproportionate to what occurred during pregnancy. Palpitations or awareness of an irregular heartbeat.

The problem is that every one of these symptoms can be attributed to “normal postpartum adjustment” by a clinician who is not looking for heart failure. This is where the diagnostic delay occurs. A retrospective analysis found that 34% of women with PPCM were initially diagnosed with postpartum depression or anxiety. The median delay from symptom onset to correct cardiac diagnosis was seven days. Seven days of heart failure left untreated.

Women don’t die from what they have. Women die from what they hold.

The woman holds her symptoms because she does not want to seem dramatic. She holds her complaints because the healthcare system has taught her that her concerns will be minimized. She holds her fear because everyone tells her this is normal. She holds it until she cannot breathe lying flat, and by then her ejection fraction is 28%.

Treatment Is Standard Heart Failure Therapy

Once diagnosed, PPCM treatment follows guideline-directed medical therapy for heart failure with reduced ejection fraction. The 2022 AHA/ACC/HFSA guidelines apply, with modifications for pregnancy and breastfeeding status.

If the patient is still pregnant, medication options are limited. Hydralazine and nitrates can be used for afterload reduction. Beta-blockers are generally safe. Diuretics can be used cautiously. ACE inhibitors and ARBs are teratogenic and cannot be used until delivery.

After delivery, the full heart failure regimen becomes available. ACE inhibitors or ARNIs form the cornerstone. Carvedilol or metoprolol are the preferred beta-blockers. Mineralocorticoid receptor antagonists like spironolactone are added when tolerated. SGLT2 inhibitors are now included in standard heart failure therapy, though data specific to PPCM populations remains limited.

Anticoagulation is a specific consideration. Women with PPCM have elevated risk of left ventricular thrombus, particularly when ejection fraction falls below 35%. The American College of Cardiology recommends considering anticoagulation in this setting, with warfarin or low-molecular-weight heparin during pregnancy and direct oral anticoagulants after delivery if not breastfeeding. 4 / Promising

Bromocriptine, the prolactin blocker, remains controversial. The German data showed benefit. The medication is approved for PPCM treatment in some European countries. In the United States, it is not standard of care. The trade-off is lactation suppression, which many women find unacceptable. The decision requires shared decision-making with the patient about her priorities.

The critical point is that treatment must start immediately upon diagnosis. Every day of delay allows further myocardial remodeling. Every day of volume overload increases the burden on an already failing ventricle.

The Racial Disparity That Demands Explanation

Black women in the United States develop peripartum cardiomyopathy at 5.3 times the rate of White women. This is not a subtle disparity. This is a chasm.

The reasons are multiple and compounding. Black women have higher rates of chronic hypertension. They have higher rates of preeclampsia. They have higher rates of obesity and diabetes. These conditions all create the oxidative stress environment that triggers PPCM in susceptible individuals.

But the disparity is not fully explained by risk factors. Even after adjusting for comorbidities, Black women still have significantly higher PPCM incidence. Genetic factors may play a role. Variants in the TTN gene, which encodes the protein titin, are found in approximately 15% of PPCM cases. These variants are found at similar rates across racial groups, so they do not explain the disparity. Other genetic modifiers remain under investigation.

What is clear is that Black women face longer diagnostic delays. Their symptoms are more likely to be dismissed. They are less likely to receive guideline-directed medical therapy once diagnosed. A 2022 systematic review in Current Problems in Cardiology documented these disparities across multiple studies. 5 / Solid

The solution requires systemic change. Every postpartum Black woman who reports orthopnea needs an echocardiogram, not reassurance. Every clinic serving a high-proportion Black population needs PPCM awareness training. Every hospital discharge protocol needs explicit instructions about warning symptoms and when to return.

This is not about making Black women responsible for their own advocacy. This is about making healthcare systems responsible for not killing Black women through diagnostic delay.

Recurrence Risk in Future Pregnancies

One of the most common questions I hear in clinic: Can I have another baby?

The answer depends almost entirely on whether the ejection fraction recovered. Full recovery is defined as EF above 50% at one year after diagnosis. Approximately 50% of women with PPCM achieve this. The other 50% have persistent dysfunction requiring lifelong heart failure management.

For women whose EF fully recovered, recurrence risk in a subsequent pregnancy is approximately 20%. This is not zero. One in five women will develop PPCM again. But the majority will carry a pregnancy successfully with close monitoring.

For women whose EF never normalized, the calculus changes dramatically. Recurrence risk exceeds 50%. Maternal mortality in the recurrent pregnancy approaches 25% in some series. This level of risk leads most cardiologists, myself included, to counsel against subsequent pregnancy. 4 / Promising

The counseling conversation requires nuance. Some women with recovered EF will decide that 20% recurrence risk is too high. Some women with persistent dysfunction will decide that they want to proceed despite the risks. These are not medical decisions alone. They are existential decisions about family, identity, and acceptable risk. My role is to ensure the woman has accurate numbers, not to make the decision for her.

What is non-negotiable is that any woman with a history of PPCM who becomes pregnant again must be followed by a cardio-obstetrics team. Serial echocardiograms during pregnancy. Monthly cardiac evaluations in the third trimester. Delivery planning with cardiology and anesthesiology at the table. This is not optional monitoring. This is the minimum standard of care.

The Advocacy Demand

I end every clinic visit with a PPCM patient the same way. I give her a card listing the warning symptoms. I tell her that if any of these symptoms appear in a future pregnancy, she should go directly to the emergency department and say the words “peripartum cardiomyopathy” out loud. She should not accept reassurance. She should not accept “this is normal.” She should demand an echocardiogram.

This is not how medicine should work. Patients should not need to become their own advocates to avoid dying from a treatable condition. But until obstetric training programs routinely teach PPCM recognition, until emergency departments have PPCM on their differential for every postpartum woman with dyspnea, until the 5.3-fold disparity affecting Black women is acknowledged and addressed, patient advocacy remains necessary.

The symptoms that should trigger immediate evaluation: orthopnea, paroxysmal nocturnal dyspnea, persistent cough, rapid weight gain, disproportionate edema, palpitations. Any of these in the last month of pregnancy or first five months postpartum requires cardiac evaluation. Not next week. Today.

At your next postpartum visit, if you have any of these symptoms, do not leave without an echocardiogram ordered. If your provider says “this is normal postpartum fatigue,” hand them this article and ask them to document their decision not to pursue cardiac evaluation. Documentation changes behavior. When a provider must write “patient complained of orthopnea, declined echocardiogram due to presumed normal postpartum fatigue,” they often reconsider.

You should not have to fight for your own survival. But until the system changes, you must.

Frequently Asked Questions

How do I know if my postpartum shortness of breath is serious?

The critical distinguishing symptom is orthopnea, the inability to breathe comfortably while lying flat. Normal postpartum fatigue makes you tired. It does not make you unable to sleep horizontally. If you need to prop yourself up on multiple pillows to breathe at night, or if you wake up suddenly gasping for air, these are cardiac warning signs. The 2010 ESC Working Group on PPCM identified orthopnea in 89% of women with the condition, compared to fewer than 5% of healthy postpartum controls. This single symptom has an 18-fold difference in prevalence between sick and healthy women. Do not accept reassurance if you cannot breathe lying flat. Demand an echocardiogram.

Can I breastfeed if I have peripartum cardiomyopathy?

Yes, with appropriate medication selection. The standard heart failure medications that form the backbone of PPCM treatment are largely compatible with breastfeeding. ACE inhibitors including enalapril and lisinopril are excreted in minimal amounts in breast milk. Metoprolol and carvedilol are considered safe. Spironolactone is acceptable. The exception is bromocriptine, which blocks prolactin and will suppress lactation entirely. If your physician recommends bromocriptine to accelerate cardiac recovery, this decision requires explicit discussion of your breastfeeding goals. Some women prioritize cardiac recovery; others prioritize breastfeeding. Both are valid choices. The decision should be yours, informed by accurate information about the trade-offs.

What is my risk of PPCM recurring in a future pregnancy?

Your recovery trajectory determines your risk. If your ejection fraction fully recovered to above 50% at one year after diagnosis, your recurrence risk in a subsequent pregnancy is approximately 20%. This means 80% of women with recovered PPCM will not develop the condition again, though close monitoring remains essential. If your ejection fraction never normalized, the picture is different. Recurrence risk exceeds 50%, and maternal mortality in the recurrent pregnancy can approach 25%. This level of risk leads most cardiologists to recommend against subsequent pregnancy. Before attempting conception, every woman with a PPCM history needs cardio-obstetrics consultation to establish her individual risk profile.

Why is peripartum cardiomyopathy more common in Black women?

Black women in the United States develop PPCM at 5.3 times the rate of White women, according to a 2015 Circulation analysis of over 5 million deliveries. This disparity reflects multiple compounding factors. Black women have higher baseline rates of chronic hypertension, preeclampsia, and diabetes, all of which create the oxidative stress that triggers PPCM. But comorbidities do not fully explain the gap. Black women also face longer diagnostic delays because their symptoms are more likely to be dismissed. They are less likely to receive guideline-directed medical therapy once diagnosed. Genetic variants in cardiomyopathy genes may contribute, but research in this area remains limited. What is practical now is clinical vigilance: every Black woman with postpartum orthopnea needs an echocardiogram urgently.

How long does recovery from peripartum cardiomyopathy take?

Most cardiac recovery occurs in the first six months after diagnosis, with the majority of improvement seen in the first three months. Approximately 50% of women achieve full recovery, defined as ejection fraction above 50%, by one year. The remaining 50% have persistent left ventricular dysfunction requiring lifelong heart failure therapy. Serial echocardiograms are essential to track your trajectory. Standard intervals are 6 weeks, 3 months, 6 months, and 12 months after diagnosis. If your EF is improving at each interval, recovery is likely. If your EF plateaus below 50%, you will need ongoing cardiology follow-up, medication optimization, and potentially advanced therapies including device implantation if your EF remains below 35% despite medical therapy.